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Abstract
Despite the production of neutralizing antibodies to hepatitis C virus (HCV), many patients fail to clear the virus and instead
develop chronic infection and long-term complications. To understand how HCV infection perturbs the antibody repertoire
and to identify molecular features of antibody genes associated with either viral clearance or chronic infection, we
sequenced the V(D)J region of naı ¨ve and memory B cells of 6 persons who spontaneously resolved an HCV infection (SR), 9
patients with a newly diagnosed chronically evolving infection (CE), and 7 healthy donors. In both naı ¨ve and memory B cells,
the frequency of use of particular antibody gene subfamilies and segments varied among the three clinical groups,
especially between SR and CE. Compared to CE, SR antibody genes used fewer VH, D and JH gene segments in naı ¨ve B cells
and fewer VH segments in memory B cells. SR and CE groups significantly differed in the frequency of use of 7 gene
segments in naı ¨ve B cell clones and 3 gene segments in memory clones. The nucleotide mutation rates were similar among
groups, but the pattern of replacement and silent mutations in memory B cell clones indicated greater antigen selection in
SR than CE. Greater clonal evolution of SR than CE memory B cells was revealed by analysis of phylogenetic trees and CDR3
lengths. Pauciclonality of the peripheral memory B cell population is a distinguishing feature of persons who spontaneously
resolved an HCV infection. This finding, previously considered characteristic only of patients with HCV-associated
lymphoproliferative disorders, suggests that the B cell clones potentially involved in clearance of the virus may also be those
susceptible to abnormal expansion.
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Introduction
Deciphering the humoral immune response to hepatitis C virus
(HCV) has been challenging. Although virus-specific antibodies
are produced in essentially all persons infected with HCV, about
80% of these patients develop persistent infection and are at risk of
long-term complications [1,2]. The most prevalent of these
complications are liver cirrhosis and hepatocellular carcinoma
[3], but HCV-infected persons may also develop mixed cryoglob-
ulinemia (MC) and B cell non-Hodgkin lymphoma (B-NHL) [4–
6]. It is therefore thought that B cells are largely ineffective in
resolving HCV infection while they are responsible for its
lymphoproliferative complications. Greater understanding of the
B cell response to HCV may help predict the outcome of the
infection in individual patients as well as their risk of developing
lymphoproliferative disorders. However, studying the B cell
(antibody) response to HCV has been extremely difficult due to
the heterogeneous nature of HCV, the lack of a practical and
readily available cell culture system to screen antibodies, and the
limited resources for studying HCV infection in chimpanzees, the
only species susceptible to HCV infection other than humans [7].
At present, knowledge about the B cell response to HCV in
humans is limited to two kinds of data. First, it is known that
patients’ sera contain antibodies that have neutralizing properties
in vitro. Such neutralizing antibodies have been found in both self-
limiting (i.e. spontaneously resolving) [8] and chronically evolving
[9–11] HCV infections. Second, there is some information on the
repertoire of antibody variable heavy (VH) and variable light (VL)
genes of whole (unfractionated) B cell populations in liver and
blood. So far, the antibody repertoire has been analyzed only in
chronic infections. In particular, it has been studied in chronically
infected patients with lymphoproliferative disorders (MC or B-
NHL) for the purpose of detecting subclinical (MC) or frankly
malignant (B-NHL) clonal B cell expansions [12–20]. There is,
however, no knowledge of the antibody repertoire in patients with
self-limiting HCV infection and, importantly, no published study
has reported on the antibody repertoire in the two distinct B cell
subsets: naı ¨ve and memory.
Diversity in the repertoire of antibody H chains is mainly
achieved during normal B cell ontogeny (maturation) by random
recombination of VH, D, and JH segments and by enzymatic
modification (addition or deletion of short coding sequences at the
VD and DJ joints) of the VHDJH junctions [21]. Single VH, D and
JH genes are chosen from a repertoire consisting of approximately
40 functional VH gene segments (that are grouped into 7
structurally related families on the basis of at least 80% nucleotide
sequence identity), 25 D segments and 6 JH segments. An
additional process of sequence diversification is achieved by
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encounter antigens, undergo rapid clonal expansion and seed
germinal centers, thereby developing into memory B cells that
express the distinctive CD27 surface protein [21,22]. Therefore,
somatically mutated variable region genes are the hallmark of
memory B cells and their progeny. Although the process of
somatic hypermutation has an element of randomness, antigen
selection tends to cluster silent (S) mutations in the antibody
framework regions (FRs), which are required to maintain
structural integrity, while replacement (R) mutations are more
often found in the complementarity-determining regions (CDRs),
which form the antigen binding sites [21,23–25].
The H chain CDR 3 (CDR3H), located at the junction of the
VH, D, and JH segments, is the most diverse region in the antibody
molecule. For this reason, it is considered to represent a molecular
footprint of the overall antibody repertoire. Structurally, the
CDR3H is located in the center of the antigen-binding site and
interacts directly with other CDRs and FRs from both H and L
chains, as well as with the antigen itself [26]. Its length varies in a
Gaussian-like distribution in physiological conditions, while
alterations away from this normal profile suggest B cell selection
and clonal expansion [27,28]. Changes in the length and amino
acid composition of CDR3H directly affect the charge, hydropho-
bicity, size and shape of the antigen-binding site [29] and, thus, the
ability of the antibody to bind antigen. The present study was
therefore conducted to investigate potential differences in the
antibody repertoire of persons who spontaneously resolved HCV
infection and from subjects who became chronically infected with
HCV. For this purpose, we cloned and sequenced the DNA of the
V(D)J region of naı ¨ve and memory B cell fractions and determined
the frequency of usage of individual VH, D and JH families and
subfamilies in these two clinical populations and in healthy
persons.
Results
To understand if and how HCV infection perturbs B cell
antigen receptor (antibody) repertoire and how this is associated
with the outcome of HCV infection, we cloned and sequenced the
V(D)J region of circulating CD27
2 (naı ¨ve) and CD27
+ (memory) B
cells from 7 healthy donors (HD), 6 persons who spontaneously
resolved (SR) an HCV infection, and 9 patients with chronically
evolving (CE) HCV infection (Table 1).
First, we determined the frequency of usage of individual VH,D
and JH subfamilies in the three clinical groups (Figure 1). In naı ¨ve
B cell clones, the most abundant VH subfamilies in all three groups
were VH1 and VH3 and, of the other VH subfamilies, only VH4
and VH5 were also found (Figure 1A). The overall pattern of VH
usage was significantly associated with clinical group in the
pairwise comparison between SR and CE (p=0.002, chi-square
test); at the subfamily level, these two patient groups gave
significant associations in the use of VH1, VH3 and VH5. In
contrast, no significant association in VH usage was found in
comparisons of HD to either SR (p=0.06) or CE (p=0.13). In
memory B cell clones (Figure 1B), the pattern of prevalent VH1
and VH3, followed by VH5, was maintained although a small
percentage of clones also used VH6 and VH7; statistical
significance was observed for the comparison between HD and
SR (p=0.027, attributable to VH1 and VH5), but not for HD vs.
CE (p=0.24) or SR vs. CE (p=0.11). For the D gene family
(Figure 1C, D), both naı ¨ve and memory B cell clones used D1–D7
as well as DIR, and the D3 subfamily was predominant. In naı ¨ve
clones (Figure 1C), the pattern of usage was significantly associated
with clinical group for the comparison SR vs. CE (p=0.021,
attributable to D4 and DIR) but not between HD and either SR
(p=0.43) or CE (p=0.09). In memory clones (Figure 1D), the
usage patterns were significantly associated with group in
comparisons between HD and SR (p=0.009, attributable to D4
and D5) and between SR and CE (p=0.018, attributable to D2
and D5), but not between HD and CE (p=0.68). Finally, of the six
JH subfamilies, all were used to some extent except JH2;
subfamilies JH4 and JH6 were prominent in both naı ¨ve and
memory clones (Figure 1E, F). In naı ¨ve clones (Figure 1E), usage
patterns were significantly associated with group in the compar-
ison between SR and CE (p=0.003, attributable to JH1, JH4 and
JH5) but not between HD and either SR or CE (p=0.26 and
p=0.19, respectively). Similarly, in memory clones (Figure 1F), a
significant association was found in the comparison of the two
patient groups SR and CE (p=0.039, attributable to JH1) but not
in comparisons between HD and either SR or CE (p=0.36 and
p=0.06, respectively). This analysis suggests that, despite general
similarities in the use of VH, D and JH subfamilies between naı ¨ve
and memory B cell clones, the patterns of subfamily usage in the
three clinical groups differ, especially between SR and CE, and
that within these groups the proportions of individual subfamilies
in naı ¨ve B cells do not always match the proportions of the
corresponding subfamilies in memory B cells.
We next identified the specific gene segments used by the three
clinical groups, beginning with the subset of 704 clones
representing naı ¨ve B cells (Figure 2). Overall, we identified 26
different VH family gene segments in HD, 29 in SR, and 31 in CE;
13 of these gene segments were used by all three groups. The
numbers of D family gene segments found in HD, SR and CE
clones were 29, 26 and 34, respectively, and 15 gene segments
were in common. Finally, we identified 7, 7 and 11 different JH
family gene segments in the same clinical groups (5 in common).
Table 1. Demographic, clinical, and virological parameters for
6 Caucasian persons who spontaneously resolved (SR) an HCV
infection and 9 Caucasian patients with a recently diagnosed
chronically evolving (CE) HCV infection.
Subject
Age
(yr) Sex
HCV
Genotype
ALT
(U/l)
HCV RNA
(IU/ml)
Anti-HCV
Abs
(cleared virus)
SR1 48 F 1b 25 - +
SR2 61 F 2a 15 - +
SR3 35 M 2a 37 - +
SR4 50 M 1b 28 - +
SR5 65 M 2a/2c 41 - +
SR6 58 F 1a 39 - +
(persistent virus)
CE1 47 F 1b 67 17,902 +
CE2 29 F 2a/2c 58 297,411 +
CE3 35 F 1b 74 56,693 +
CE4 65 M 1b 84 1,930,060 +
CE5 50 M 2a 55 405,357 +
CE6 56 F 1b 211 2,388,080 +
CE7 59 M 1a 95 985,380 +
CE8 48 M 1b 45 373,745 +
CE9 52 F 1a 65 227,320 +
yr, years; F, female; M, male; ALT, alanine aminotransferase; Abs, antibodies.
doi:10.1371/journal.pone.0025606.t001
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in naı ¨ve B cells from CE samples compared to both HD and SR.
The same analysis was performed for the 704 clones
representing memory B cells (Figure 3). Here, we identified 33
different VH family gene segments in HD, 24 in SR, and 34 in CE;
15 gene segments were in common for all three groups. The
numbers of D family gene segments found in HD, SR and CE
clones were 32, 31 and 31, respectively; 14 gene segments were in
common. Finally, we identified 7, 9 and 8 different JH family gene
segments in the same clinical groups (6 in common). The tendency
for a wider variety of gene segments in CE samples, already
observed in clones from naı ¨ve B cells, was maintained for the VH
family versus SR only, but not for the D or JH family.
Then, the frequency of usage of individual gene segments in
clones from naı ¨ve and memory B cells was analyzed statistically for
those subfamilies that gave significant associations with clinical
group (as indicated in Fig. 1). Despite the fact that numerous gene
segments were used in common by the clinical groups, only a
limited number of alleles was significantly associated with group
(Table 2). In the analysis of naı ¨ve B cell clones (where significance
was found only between SR and CE), this included one VH1 gene
segment, namely IGHV1-69*01, as well as two VH3 gene
segments and one each from the D4, JH1, JH4 and JH5 subfamilies;
no significant association was found for VH5 or DIR. In the
analysis of memory B cell clones, three VH1 gene segments were
significantly associated with clinical group in the comparison of
HD and SR and, comparing SR and CE, a significant association
was found for one gene segment each in subfamilies D2, D5 and
JH1. Altogether, this analysis shows that B cells from the three
clinical groups differ in the frequency of usage of particular V(D)J
gene segments.
Each VH gene segment was then scrutinized for somatic
mutations with respect to the germline gene with highest sequence
similarity (Table 3). An unmutated germline sequence was found
in a small percentage of clones from naı ¨ve B cells from all three
clinical groups, whereas clones from memory B cells all contained
mutations. Naı ¨ve B cell clones from HD tended to have a low rate
of mutation, with over 60% of clones being categorized in the
#2% mutated nucleotide class; in SR and CE, the percentage of
clones in this low mutation category were 36.5% and 47.6%.
Figure 1. Frequency of usage of V(D)J subfamilies in molecular clones of naı ¨ve and memory B cells from 7 healthy donors (HD), 6
persons who spontaneously resolved an HCV infection (SR) and 9 patients with chronically evolving HCV infection (CE). For each
subject, 32 clones from naı ¨ve B cells and another 32 from memory B cells were analyzed. Values represent the percentage of subfamily use for all
clones in a particular clinical group and B cell subset. Panels A, C and E, naı ¨ve B cell clones; panels B, D and F, memory B cell clones. Associations
between clinical group and individual subfamily were tested for significance with chi-square or Fisher’s exact test only when a previous chi-square
test indicated a significant association of gene family usage in a pairwise comparison of groups; p values are shown only when #0.05.
doi:10.1371/journal.pone.0025606.g001
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all HD clones being categorized in the .2% nucleotide mutation
class; in SR and CE, these values were lower (84.3% and 75.8%,
respectively). These findings suggest that B cells recently exposed
to HCV, irrespective of infection outcome, have a general
perturbation in their mutation rate.
The VH gene mutation frequency was then determined for
naı ¨ve and memory B cell clones from each individual and
averaged per clinical group (Figure 4). The mutation frequency
was low (2%–3%) for naı ¨ve B cell clones, without a significant
association with clinical group (one-way ANOVA, p=0.61)
(Fig. 4A). For memory B cell clones, these values were about
two-fold higher, again without a significant association with group
(p=0.17) (Fig. 4B). However, the mutation frequency of VH gene
sequences from all memory B cell clones together was significantly
higher than that of naı ¨ve B cell clones (p,0.001, chi-squared test).
Given the higher mutation frequency in memory B cell clones,
these genes were further investigated in terms of R and S
mutations and their distribution in FR and CDR along the VH
gene (Figure 5A, B). A significant association between R mutation
frequency and clinical group was observed in FR2 and FR3, with
the highest value in HD and the lowest value in SR. In CDR1 and
CDR2, the frequencies of R and S mutations were similar among
groups, yet SR had the highest frequency of R mutations and the
Figure 2. Naı ¨ve B cells: fractional usage of individual V(D)J gene segments in molecular clones from healthy donors (HD), persons
who spontaneously resolved an HCV infection (SR) and patients with chronically evolving HCV infection (CE).
doi:10.1371/journal.pone.0025606.g002
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SR having a higher R:S ratio for CDR (14.8) than either HD (3.5)
or CE (4.4), suggesting antigen selection (Figure 5A). To further
understand if the somatic mutation pattern in memory B cell
clones was characteristic of antigen selection, each VH gene was
analyzed for the probability that the numbers of R mutations in
FR and CDR occurred by chance. This probability was assessed
using a mathematical algorithm, whereby the expected mutations
were compared to the observed mutations, and p values were
calculated on the basis of a multinomial distribution. Genes with
low p value (,0.05) for both FR and CDR were considered to
have undergone antigen selection. This analysis revealed that, on
average, 35.4% of VH genes in SR group had undergone antigen
selection (SD=14.6%) compared to 11.1% (SD=12.6%) in CE
(Figure 5B). Altogether, these results suggest that, despite similar
VH mutation frequencies in memory clones from the three clinical
groups, a distribution of R and S mutations characteristic of
antigen selection was more evident in SR than in CE.
To visualize the lineage relationship among antigen-selected
sequences, we constructed phylogenetic trees for memory B cell
VH sequences from each study subject. In general, in trees from
HD and CE, sequences were well distanced from nodes and from
each other along long branches, suggesting sequence diversity. By
contrast, in SR trees, multiple sequences were clustered on short
Figure 3. Memory B cells: fractional usage of individual V(D)J gene segments in molecular clones from healthy donors (HD),
persons who spontaneously resolved an HCV infection (SR) and patients with chronically evolving HCV infection (CE).
doi:10.1371/journal.pone.0025606.g003
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(Figure 5C).
To further assess antibody repertoire variations in memory B
cell clones, we calculated average CDR3 length per subject and
then per study group (Figure 5D). Mean CDR3 length was about
15 residues in HD and CE groups but only about 13 residues in
SR (ANOVA p=0.034, Newmann-Keuls post test, p,0.05 for SR
vs. both HD and CE). The shorter CDR3 length in SR suggested a
mobilization of the antibody repertoire due to clonal selection.
This possibility was confirmed by spectratyping of CDR3 PCR
products (Figure 5E), which showed a physiological, Gaussian-like
distribution of lengths in HD, a slight deviation from a normal
profile in CE, but a complete loss of this pattern with prominent
peaks in SR.
Finally, to determine if the observed molecular differences
between memory B cells from SR and CE had functional
correlates, we assessed the ability of freshly purified CD27
+ B
cells to proliferate upon in vitro stimulation with recombinant
HCV antigens, by measuring the dilution of the division-tracking
dye CFSE after 7 days. For CE samples, mean stimulation index
was ,2 for all HCV antigens, indicating no proliferative response
(Figure 6A). For SR, stimulation index was negative for all
antigens but NS5, which produced an abundant proliferative
response (Figure 6B). This finding suggests a role of antibody
against NS5 in viral clearance.
Discussion
This study provides a snapshot view of the antibody repertoire
of HCV-infected persons shortly after their spontaneous recovery
(SR) or in the early period of a chronically evolving infection (CE).
In both naı ¨ve and memory B cell subsets, the frequency of usage of
particular antibody gene subfamilies and segments (alleles) varied
in SR, CE and healthy donors (HD), with particular differences
between SR and CE. Within these latter two groups, a reversed
expression of a few subfamilies distinguished naı ¨ve from memory B
cells. Compared to CE, the antibody genes of SR were composed
of fewer VH, D and JH gene segments in naı ¨ve B cells and fewer
VH segments in memory cells. Although the nucleotide mutation
rate was similar among clinical groups, the pattern of replacement
and silent mutations in memory B cell clones gave evidence for
greater antigen selection in SR than CE samples. Greater clonal
evolution of SR than CE memory B cells was also supported by
analysis of phylogenetic trees and CDR3 lengths. Finally, freshly
purified B cells from SR but not CE gave a proliferative response
to in vitro stimulation with NS5 HCV-SOD fusion protein.
The most intriguing finding of this study is that antibody V(D)J
sequences are encoded by a smaller number of germline elements
in naı ¨ve and memory B cells from persons who spontaneously
resolved an HCV infection than from patients with a chronically
evolving infection. Until now, a restricted repertoire of antibody
variable heavy (VH) genes and a clustering of VH gene somatic
mutations have been regarded as hallmarks of HCV-associated
MC and B-NHL and have been interpreted as direct consequenc-
es of persistent antigenic stimulation of B cells [12–17,19,30]. We
instead found that these features are common to self-limiting
infections: this suggests that B cell clones that are potentially
involved in clearance of the virus are also those susceptible to
abnormal clonal expansion. This speculation is consistent with a
recent study by Charles et al. [31], who found that some patients
with HCV-associated MC expressed a common subset of clonally
expanded, weakly hypermutated, antibody gene segment-restrict-
ed, memory-like B cells.
Particularly puzzling are the differences of the V(D)J repertoire
between naı ¨ve and memory B cells of the CE group. For example,
we observed that some genes were relatively enriched in memory
B cells but depleted in naı ¨ve B cells; this difference could be due to
the transfer of some B cells from the CD27
2 to the CD27
+ subset
because of their memory differentiation. Other genes were
characterized by a relative enrichment in naı ¨ve B cells but a
depletion in memory B cells; this pattern may be due to changes in
B cell selection or to the presence within the CD27
2 fraction of
atypical memory B cells that have undergone isotype switching
and somatic hypermutation, but have downregulated CD27. Our
finding of the highest percentage of naı ¨ve B cell clones with .2%
mutated nucleotides in the CE group supports this possibility.
These atypical memory B cells have already been described by our
group [32] and have recently been detected in HIV-infected [33]
and Plasmodium falciparum-infected [34,35] individuals. They have
been named ‘exhausted’ memory B cells because of their increased
expression of inhibitory receptors, altered expression of homing
Table 2. Frequency of usage of V(D)J gene segments in 1408
molecular clones from 7 healthy donors (HD), 6 persons who
spontaneously resolved (SR) an HCV infection and 9 patients
with chronically evolving (CE) HCV infection, by B cell subset.
Gene segment Frequency, % p value
HD SR CE HD vs. SR SR vs. CE
Naı ¨ve B cells
IGHV1-69*01 7.0 18.5 2.9 ND ,0.001
IGHV3-21*01 12.3 3.7 15.5 ND 0.004
IGHV3-23*01 3.5 2.8 11.7 ND 0.015
IGHD4-17*01 1.8 16.7 3.9 ND 0.003
IGHJ1*01 0.0 0.0 4.9 ND 0.026
IGHJ4*03 10.5 23.1 7.8 ND 0.002
IGHJ5*01 8.8 3.7 14.6 ND 0.007
Memory B cells
IGHV1-2*02 9.2 1.2 6.1 0.028 ND
IGHV1-8*01 7.9 0.0 6.1 0.011 ND
IGHV1-46*01 3.9 13.3 7.1 0.050 ND
IGHD2-2*01 3.9 1.2 9.4 ND 0.022
IGHD5-5*01 2.6 4.9 0.0 ND 0.042
IGHJ1*01 2.6 7.2 0.0 ND 0.008
Chi-square or Fisher’s exact test was performed for individual gene segments
only when the pairwise comparison of two clinical groups gave a significant
association at the subfamily level; data are shown only when p#0.05.
ND, not determined (no significant association at gene subfamily level).
doi:10.1371/journal.pone.0025606.t002
Table 3. Percentages of B cell molecular clones with somatic
mutations in VH gene, by B cell fraction and clinical group.
Mutation frequency Naive B cell clones, % Memory B cell clones, %
HD SR CE HD SR CE
No mutations 2.9 3.1 1.9 0 0 0
#2% of all nucleotides 60.9 36.5 47.6 6.6 15.7 24.2
.2% of all nucleotides 36.2 60.4 50.5 93.4 84.3 75.8
doi:10.1371/journal.pone.0025606.t003
B Cell Repertoire In HCV Infection
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25606receptors, reduced proliferative potential and stunted replication
history and immunoglobulin diversity [36].
The studyalsorevealsthattheantibody V(D)Jsequencesof naı ¨ve B
cells from both SR and CE lack molecular signs (e.g. high mutation
rate) of current activation. This result contrasts with the idea that
HCV-associated abnormal clonal B cell populations arise from naı ¨ve
B cells and does not confirm the phenotypic findings of high levels of
activated naı ¨ve B cells in the blood of HCV
+ patients with MC [37].
The finding that B cellsfrom SR proliferated upon stimulation with a
nonstructural HCV antigen (NS5) proves that these cells are specific
for this protein. Whether this specificity contributes to infection
control because it is expressed by direct antibody generation or,
alternatively, by CD4 T cell help remains to be determined. Indeed,
our understanding of the direct role of antibodies in viral protection
and disease outcome emerges from numerous clinical and experi-
mental observations, as summarized here. Patients suffering from
agammaglobulinemia experience an accelerated disease progression
[38]. Immunoglobulin produced from pooled human plasma
negative for anti-HCV antibodies transmitted hepatitis C to
chimpanzee recipients, while that from unscreened pooled plasma
was found to contain neutralizing antibodies that prevented infection
[39]. Polyclonal antibodies isolated from a chronic HCV-infected
patient protected chimeric mice against in vivo challenge with
different HCV genotypes, although the efficacy of such cross-
genotype neutralization was lower than that predicted by cell culture
experiments [40]. In HCV-infected liver transplant recipients, the
HCV variants that infected the liver grafts werepoorly neutralized by
antibodies present in the patients’ pre-transplant sera (rather than
variants no longer detected after transplantation) [41]. Finally, while
in self-limiting infections neutralizing antibodies can be rapidly
detected in the serum and progressively decrease or even disappear
after recovery, in chronically evolving infections they appear later and
tend to persist [8,42].
There are some caveats associated with the current study. First,
memory B cells used in the experiments reported here were not
selected for antigen specificity, due to the well-known technical
difficulties of achieving pure cell populations. This may have
biased our results given that it is unclear how representative the
overall B cell repertoire (which is not shaped only by HCV) is of
the HCV-specific B cell compartment. On the other hand, by
using whole B cells, we did not exclude from study those cells that
are involved in the immune pathogenesis of HCV infection but
that do not directly bind the viral particle. This permitted us to get
a more complete picture of the B cell response to HCV. Second,
some sequences might have been cloned more readily than others
after PCR amplification. To minimize the risk of frequency
underestimation, we extended the number of clones up to 32 per B
cell subset per patient: as already demonstrated, when an adequate
number of templates is amplified, results of PCR-cloning do not
significantly differ from those obtained by single genome analysis
[43]. In addition, we used degenerated primers to amplify all VH
families and intentionally omitted pre-PCR sampling (i.e. single-
cell sorting) to avoid potential underestimation of the genetic
diversity of the antibody sequences. Another limitation of the study
is the small number of subjects studied, due to the fact that
conducting such an extensive and articulated work is difficult in a
larger sample. Therefore, these findings should be confirmed by
further studies in other larger and more diverse HCV-positive
populations (i.e. patients before and after complete viral
eradication, anti-HCV therapy responders vs. non-responders,
persons with different IL-28B genotypes).
In conclusion, this study found that pauciclonality of the memory
B cell population is characteristic of persons who had a recent, self-
limiting HCV infection. This observation leads us to hypothesize a
model of pathogenesis in which the antibody response to HCV may
follow three different pathways: 1) selected B cell subsets are
activated, undergo memory differentiation and clonal expansion,
produce hypermutated and affinity-matured antibodies and then
contract when viral clearance is achieved (resolved infection); 2) B
cell subsets areactivated as in scenario 1 but continue to abnormally
expand if antigen persists (chronic infection complicated by MC);
and 3) B cells are not efficiently activated and produce low-affinity
antibodies without protective ability (chronic infection without
MC). It is currently unknown why, in some patients, an initially
successful B cell response deviates towards a proliferative disorder
(scenario 2), but both viral and host factors may be involved.
Whether ourdata might be used to informtherapeutic interventions
or vaccine development in terms of antigen design or dosing
remains to be assessed. Future studies should indeed compare SR
and CE groups for differences in B cell epitopes of the virus, HLA
polymorphisms, and B-T cell cognate interactions.
Materials and Methods
Study subjects and biological samples
Peripheral blood samples were obtained from 7 healthy donors
(HD), 6 patients who had spontaneously resolved an acute HCV
infection in the 6 months prior to sampling (spontaneous resolvers,
Figure 4. Mutation frequencies of VH gene segments in molecular clones of naı ¨ve B cells (A) and memory B cells (B), by clinical
group. Values are mean (SD) of the per-subject average (32 clones per subject). p,0.001, all naı ¨ve vs. all memory clones, chi-squared test.
doi:10.1371/journal.pone.0025606.g004
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HCV infection (chronically evolving, CE), defined as an infection
of at least 6 months’ duration. All subjects were Caucasian,
negative for antibodies to human immunodeficiency virus,
antibodies to hepatitis B virus, hepatitis B surface antigen, serum
rheumatoid factor and cryoglobulins. None had ever had antiviral
therapy nor a diagnosis of lymphoproliferative disorders.
The study protocol was approved by the University of Bari
Medical School Ethics Committee and conformed to the good
clinical practice guidelines of the Italian Ministry of Health and
the ethical guidelines of the Declaration of Helsinki, as revised and
amended in 2008. Written informed consent was obtained from
each subject.
Cell preparations
Peripheral blood mononuclear cells (PBMC) were separated by
Ficoll-Hypaque (Pharmacia Biotec, Uppsala, Sweden) density
gradient centrifugation. B cells were isolated from PBMC by
automated magnetic cell sorting using the B Cell Isolation Kit II
(Miltenyi Biotec). B cells were further fractionated into naı ¨ve
(CD27
2) and memory (CD27
+) populations by automated
magnetic cell sorting with anti-CD27 microbeads (Miltenyi
Biotec). All sorted cell populations exhibited .95% purity, as
revealed by staining with either peridin chlorophyll protein-
conjugated anti-CD19 or fluorescein isothiocyanate-conjugated
anti-CD27, followed by analysis with a FACSCanto (Becton
Dickinson) cytometer and FlowJo software (Tree Star) (Figure S1).
Isolated cells were cryopreserved until use.
Amplification, cloning and sequencing of the V(D)J gene
region
Genomic DNA was extracted from naı ¨ve and memory B cell
fractions using the BioRobot EZ1 Workstation and the EZ1 DNA
Tissue kit (Qiagen). The V(D)J region was amplified with a semi-
nested protocol according to an established procedure [13].
Briefly, the upstream primer was complementary to the first
Figure 5. Evidence for antigen selection of VH gene segments in molecular clones from memory B cells. A Distribution of replacement (R)
and silent (S) mutations in each framework region (FR) and complementarity-determining region (CDR), by clinical group. Statistical significance by
ANOVA is indicated. B Percentage of VH gene segments with evidence of antigen selection, according to Lossos et al. [45]. Values are mean (SD) of the
per-subject average (32 clones per subject). C Representative phylogenetic trees from one healthy donor (HD), one patient who spontaneously resolved
anHCVinfection(SR),andonepatientwithchronicallyevolvingHCVinfection(CE).Thepatternofbranchingandclusteringofsequences intheSRtreeis
evidence of clonal evolution. D Length of CDR3 peptide loops deduced from VH gene nucleotide sequences of memory B cells, by clinical group. Values
aremean(SD) oftheaverage valuepersubject.ANOVAp=0.034; Newman-Keuls posttest:HDvs. SR,p=0.0.017; HDvs. CE,p=1.0;SRvs. CE,p=0.042. E
Representative CDR3 length distribution profiles determined by spectratyping on CDR3 PCR products reveal evidence of clonal selection in SR.
doi:10.1371/journal.pone.0025606.g005
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primer annealed to an outer conserved sequence of the joining
region (JH) in the first round and to an inner conserved sequence of
the same JH in the second round of amplification. PCR products
were resolved on 1.3% agarose gels stained with ethidium
bromide, and optically analyzed by ultraviolet transillumination.
The bands comprised between 350 and 400 bp were excised and
purified using the Montage DNA Gel Extraction Kit (Genomixs).
PCR products were cloned using the TOPO TA cloning system
(Invitrogen Life Technologies). Randomly selected bacterial
colonies were picked, cultured and extracted for plasmid DNA
using QIAprep Miniprep Kit (Qiagen). DNA was sequenced on
the ABI 3100 Genetic Analyzer (Applied Biosystems) using the
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems) [30]. For each subject, at least 32 clones were sequenced per
sample (naı ¨ve and memory B cells).
Analysis of V(D)J gene sequences
Results from automated DNA sequencing were inspected and
validated using Chromas Lite 2.01 software (Technelysium,
Tewantin, Australia). Only productive rearranged sequences (no
stop codons or in frame junctions) were further analyzed. For each
subject, 704 sequences were analyzed for naı ¨ve B cells and another
704 sequences for memory B cells, for a total of 1408 sequences.
The variable (V), diversity (D) and joining (J) genes and alleles
were identified by comparison with germline antibody genes, using
the International ImMunoGeneTics (IMGT) information system
(http://imgt.cines.fr) and the NIH Joinsolver (http://joinsolver.
niams.nih.gov/index.htm) with default settings. For each gene,
alleles were grouped by subfamily and expressed as a percentage in
naı ¨ve and memory subsets of each clinical group.
Using the same software, the percentage of mutated nucleotides
per VH segment was determined and used to categorize naı ¨ve and
memory clones into three groups: no mutations, #2% mutated
nucleotides or .2% mutated nucleotides as suggested by Lossos
et al. [45] Then, for each subject, the frequency of mutated VH
nucleotides was determined as the number of mutated nucleotides
divided by the total number of nucleotides, from FR1 to FR3
inclusive, for all molecular clones sequenced for the particular
person; these values, expressed as a percentage, were used to
calculate the mean (SD) mutation frequency for naı ¨ve and
memory clones for each clinical group. This same calculation
was repeated for each FR and CDR within the VH segment for
memory B cell clones, distinguishing between replacement (R) and
silent (S) mutations as indicated by the IMGT information system.
The antigen selection pressure on Ig genes was calculated
according to the multinomial distribution model of Lossos et al.
[45], using the online JAVA applet (http://www-stat.stanford.
edu/immunoglobulin/). This analysis determines, for each VH
gene segment, the probability that a scarcity of R mutations
occurred by chance in the CDRs (pCDR), as well as the
probability that an excess of R mutations occurred by chance in
the FRs (pFR). An antigen-selected sequence was defined as one
with both pFR,0.05 and pCDR,0.05. The percentage of
antigen-selected sequences per subject was calculated and then
averaged per clinical group.
Similarities in VH nucleotide sequences were identified using the
multiple sequence alignment application ClustalX2.0.9 [46].
Unrooted phylogenetic trees were constructed with ClustalX2
using distance-based neighbor-joining analysis performed on
Tamura-Nei neighbor estimates and visualized with TreeView
1.6.6. [47]. Bootstrap analyses were conducted using 1000
replicates.
CDR3 analysis
The length of each CDR3 in molecular clones from memory B
cells was determined from the deduced protein sequence by
counting the number of amino acids between the last residue of
FR3 (VH) and the first residue of JH (FR4). These values were
averaged per subject and used to determine the mean (SD) value
for each clinical group.
To obtain a graphical view of CDR3 size distributions, CDR3
DNA from memory B cell clones was amplified using FR3 and JH
primers, the PCR product was analyzed on an ABI PRISM 3100
Genetic Analyzer, and spectratyping analysis was performed using
ABI Prism 3100 GeneScan 3.7 software, as described [48].
In vitro proliferation assay
Freshly purified CD27
+ B cells were labeled with the vital dye
5(6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE; Mo-
lecular Probes), as described [32]. Labelled cells were cultured in
U-bottom 96-well plates (Falcon, BD Biosciences) in RPMI-1640
medium completed with 10% heat-inactivated fetal bovine serum
(FBS), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml
streptomycin (all from Sigma-Aldrich). Each well contained 10
5
cells in 200 ml medium. Wells in triplicate were stimulated with a
recombinant fusion protein (10 mg/ml) consisting of superoxide
dismutase (SOD) combined with one of five HCV antigens (core,
c22, aa 2–120; NS3, c33, aa 1192–1457; NS4, c100, aa 1569–
1931; NS3/NS4A, aa 1027–1711; NS5, aa 2054–2995; Chiron).
Control wells received 10 mg/ml recombinant SOD or 1 mg/ml
Figure 6. In vitro proliferation of CFSE-labelled B cells in
response to 7 days’ stimulation with different recombinant
HCV-SOD fusion proteins, by clinical group. A Stimulation index,
calculated as the percentage of cells with diluted CFSE staining
(indicating cell division) after HCV-SOD treatment relative to that of
SOD-treated control cells. SR vs. CE, p=0.011 Mann-Whitney U test after
ANOVA. B Representative FACS scatter plots of B cells from SR (left) and
CE (right) stimulated with NS5 HCV-SOD fusion protein show greater
CFSE dilution (hence proliferation) in SR.
doi:10.1371/journal.pone.0025606.g006
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atmosphere containing 5% CO2 for 7 days, and then analyzed for
CFSE fluorescence with a FACSCanto (BD Biosciences) flow
cytometer and FACSDiva software (BD Biosciences). The
percentage of CD19
+ cells with diluted CFSE staining (indicating
proliferation) was determined and averaged for triplicate samples.
The extent of proliferation was determined from the relative loss in
fluorescence, by calculating the stimulation index according to the
formula: percentage of CFSE-dilute cells in presence of antigen/
percentage of CFSE-dilute cells in absence of antigen (recombi-
nant SOD alone). These values were averaged for each antigen
and clinical group. A stimulation index 3 standard deviations
higher than the average stimulation index of healthy donor cells
was taken to indicate a proliferative response to antigen.
Statistical analysis
Statistical analyses were performed using Statistica 6.1 software
(StatSoft) and assumed independence between cell clones, i.e.
ignored any possible correlation between data obtained from
different cells from the same individual.
The patterns (frequencies) of VH, D and JH gene family use were
tested for significance with a step-by-step procedure. First, the chi-
square test was performed in pairwise comparisons of clinical
groups, separately for naı ¨ve and memory B cell subsets. When this
test indicated a significant association at the gene family level,
further statistical analyses using chi-square or, when necessary,
Fisher’s exact test were performed for gene subfamilies. Then, for
those subfamilies whose usage was significantly associated with
clinical group, chi-square or Fisher’s exact test was used again for
individual genes.
Mean percentages of nucleotide mutations and mean CDR3
lengths were compared among clinical groups by one-way
ANOVA with Newman-Keuls post test. Mean percentages of
mutations in naı ¨ve and memory B cells were compared using chi-
squared test. Stimulation indexes were compared by one-way
ANOVA with Mann-Whitney U post test. Values of p#0.05 were
assumed to be significant.
Supporting Information
Figure S1 Representative immunomagnetic purification of
CD27
+ and CD27
2 B cells.
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